Azacitidine for the treatment of patients with acute myeloid leukemia
暂无分享,去创建一个
A. Levis | V. Pavone | G. Gaidano | P. Musto | A. Venditti | F. Buccisano | D. Ferrero | A. Spagnoli | M. Lunghi | L. Maurillo | N. Di Renzo | E. Olíva | D. Pastore | A. D’Arco | A. Santagostino
[1] A. Stamatoullas,et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. , 2011, Blood.
[2] H. Kantarjian,et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. , 2010, Blood.
[3] R. Hills,et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] A. Stamatoullas,et al. Azacytidine in refractory or relapsed AML after intensive chemotherapy (IC): results of the French ATU Program , 2010 .
[5] S. Solomon,et al. Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia. , 2010, Journal of Clinical Oncology.
[6] J. Dipersio,et al. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Dombret,et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] J. Gabrilove,et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Dombret,et al. Azacytidine (AZA) as First Line Therapy in AML: Results of the French ATU Program. , 2009 .
[10] Valeria Santini,et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.
[11] R. Hills,et al. Independent Prognostic Factors for Aml Outcome Pre-treatment Prognostic Factors , 2022 .
[12] H. Dombret,et al. Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia , 2008, Haematologica.
[13] L. Silverman,et al. Azacitidine Prolongs Overall Survival (OS) and Reduces Infections and Hospitalizations in Patients (Pts) with WHO-Defined Acute Myeloid Leukemia (AML) Compared with Conventional Care Regimens (CCR) , 2008 .
[14] G. Mufti,et al. The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS) , 2008 .
[15] G. Garcia-Manero. Demethylating agents in myeloid malignancies , 2008, Current opinion in oncology.
[16] M. Lübbert,et al. Current status of epigenetic treatment in myelodysplastic syndromes , 2008, Annals of Hematology.
[17] P. Maslak,et al. Azacitidine and the beginnings of therapeutic epigenetic modulation. , 2008, Expert opinion on pharmacotherapy.
[18] Jorge Cortes,et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. , 2007, Blood.
[19] M. Grever,et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Bourhis,et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. , 2007, Blood.
[21] E. Estey,et al. Acute myeloid leukemia and myelodysplastic syndromes in older patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] R. Hills,et al. A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment , 2007, Cancer.
[23] T. Haferlach,et al. Discovery of epigenetically silenced genes in acute myeloid leukemias , 2007, Leukemia.
[24] S. Fröhling,et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.
[25] R. Shadduck,et al. Treatment of acute myelogenous leukemia with outpatient azacitidine , 2006, Cancer.
[26] R. Larson,et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[28] Yi Ning,et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. , 2006, Blood.
[29] K. Bhalla. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] F. Appelbaum,et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. , 2002, Blood.
[32] N. Harris,et al. The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.
[33] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Holland,et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] H. Kantarjian,et al. Acute myeloid leukemia , 2018, Methods in Molecular Biology.
[36] R. Clark,et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[37] Johnson M Liu,et al. Chromatin remodeling and leukemia: new therapeutic paradigms. , 1999, Blood.
[38] P. Thall,et al. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. , 1997, Blood.
[39] M. Slovak,et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.
[40] J. Herman,et al. DNA methylation changes in hematologic malignancies: biologic and clinical implications. , 1997, Leukemia.
[41] C. Bloomfield,et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French-American-British criteria: a Cancer and Leukemia Group B Study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] B. Mitchell,et al. Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside. , 1994, Leukemia.
[43] C. Schiffer,et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. , 1993, Leukemia.
[44] D. Richel,et al. The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. , 1991, British Journal of Cancer.
[45] H. Tilly,et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] B. Löwenberg,et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.